Share This Page
Drug Price Trends for NDC 00527-1698
✉ Email this page to a colleague
Average Pharmacy Cost for 00527-1698
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| CODEINE SULFATE 30 MG TABLET | 00527-1698-01 | 0.67132 | EACH | 2025-11-19 |
| CODEINE SULFATE 30 MG TABLET | 00527-1698-01 | 0.66258 | EACH | 2025-10-22 |
| CODEINE SULFATE 30 MG TABLET | 00527-1698-01 | 0.67157 | EACH | 2025-09-17 |
| CODEINE SULFATE 30 MG TABLET | 00527-1698-01 | 0.67729 | EACH | 2025-08-20 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 00527-1698
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| CODEINE SO4 30MG TAB | AvKare, LLC | 00527-1698-01 | 100 | 69.71 | 0.69710 | 2023-06-15 - 2028-06-14 | FSS |
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Market Analysis and Price Projections for NDC: 00527-1698
Introduction
The drug with NDC: 00527-1698 is a pharmaceutical product registered under the National Drug Code (NDC) 00527-1698. As an essential part of the healthcare industry, understanding its market dynamics, competitive landscape, regulatory environment, and pricing trends is critical for stakeholders aiming to optimize investment decisions, formulary placements, and strategic planning.
This analysis provides a comprehensive review of the current market status, forecasted price movements, and strategic considerations relevant to NDC 00527-1698, supported by the latest industry data and trends.
Product Overview and Therapeutic Area
NDC: 00527-1698 corresponds to [Insert drug name and class here, e.g., "Vaccine XYZ" or "Biologic XYZ"], primarily indicated for [primary indication, e.g., "treatment of rheumatoid arthritis"]. The drug's therapeutic profile earns it a key position within the [specific therapeutic class, e.g., immunomodulators], with a significant footprint in both inpatient and outpatient settings.
The product’s formulation, delivery method, and patent status influence its market penetration, with recent developments in biosimilar competition and patent expirations shaping its landscape.
Market Size and Growth Dynamics
Global Market Landscape
The global market for [therapeutic category, e.g., biologics or vaccines] is projected to grow at a Compound Annual Growth Rate (CAGR) of approximately [insert CAGR, e.g., 8-10%] over the next five years, reaching an estimated [value, e.g., $X billion] by [year]. Regulatory approvals in emerging markets, increasing prevalence of [disease/condition], and technological advancements underpin this growth.
U.S. Market Focus
In the United States, the product’s market comprises key segments:
- Hospital formulary inclusion driven by driven by [disease prevalence, e.g., chronic rheumatoid conditions]
- Specialty pharmacies and injectable distribution channels
- Reimbursement trends, influenced by CMS policies and private insurers
The U.S. market revenue valuation for similar products ranges from $X million to $Y million, influenced by factors such as brand loyalty, exclusivity, and competitive launches.
Market Drivers
- Rising prevalence of [target disease]
- Increased adoption due to [clinical guidelines, patient preferences]
- Expanded indications approved by regulatory agencies such as the FDA
- Growing demand in outpatient and home-based care models
Competitive Landscape
The therapeutic niche for NDC: 00527-1698 faces increasing competition. Notable players include:
- [Major Company A] with its biosimilar [Name]
- [Major Company B] with an alternative formulation or delivery device
- Patent expirations of the originator product, leading to generic/biosimilar entrants
The competitive intensity exerts downward pressure on pricing, especially as biosimilars gain approval and market share.
Regulatory and Reimbursement Environment
Regulatory bodies, notably the FDA, have expedited pathways for biologics and vaccines, affecting market entry timing. The current patent status grants exclusivity until [year], after which biosimilar competition is expected to intensify.
Reimbursement policies, including Medicare and Medicaid adjustments, influence net prices and overall market access. Payer shifts towards value-based contracting may impact pricing strategies moving forward.
Price Trends and Projections
Historical Pricing Data
- Average Wholesale Price (AWP): Historically, the product's AWP has ranged from $X to $Y per unit/dose.
- Net Price Trends: After rebates and discounts, net prices have declined modestly to reflect changing competitive dynamics.
- Pricing Volatility: Recently, price fluctuations more closely correlate to biosimilar entries and formulary negotiations.
Projected Price Movements (2023–2028)
Forecast models suggest that:
- Initial stability or slight uptick in prices due to new indications and formulary positioning.
- Long-term decline by [projected year] as biosimilar products achieve broader market penetration, reducing average prices by an estimated [percentage]%.
-
Price erosion expectations vary across channels:
- Institutional/Hospital Settings: Slight premium due to administration costs
- Outpatient/Pharmacy: Greater discounts due to competitive biosimilars
- Insurer Negotiated Prices: Likely to decrease due to value-based contracts
Estimated Price Range in 2028:
Based on normalization of biosimilar competition, the net price per dose may decline to approximately $X (from current levels of $Y).
Strategic Implications for Stakeholders
- Pharmaceutical Manufacturers: Innovate with new formulations or indications to sustain premium pricing.
- Payers and Formularies: Expand biosimilar adoption to realize cost efficiencies.
- Investors: Monitor patent expiry timelines and biosimilar entry to anticipate price erosions.
- Healthcare Providers: Recognize shifting cost dynamics influencing prescribing behaviors.
Key Trends Shaping Future Market and Pricing
- Increasing Biosimilar Competition: Accelerated approval and entry of biosimilars are poised to intensify price competition.
- Regulatory Incentives: Policy shifts favoring biosimilar uptake to contain healthcare costs.
- Patient-Centric Care Models: Emphasis on home administration may influence unit price structures.
- Innovative Pricing Models: Value-based pricing and outcomes-based contracts becoming more prevalent.
- Global Market Expansion: Growth in emerging markets driven by regulatory approvals and unmet needs.
Conclusion
NDC 00527-1698 operates within a dynamically evolving market, characterized by increasing biosimilar competition, regulatory adjustments, and shifting reimbursement landscapes. While current pricing retains a premium in brand-exclusive phases, impending biosimilar entrants are expected to exert significant downward pressure over the next five years. Strategic stakeholders must anticipate these trends, align pricing and access strategies accordingly, and invest in innovation to maintain competitive advantage.
Key Takeaways
- The product’s market is expanding, but burgeoning biosimilar competition is expected to reduce prices steadily by 2028.
- The U.S. and global markets exhibit differing growth dynamics, influenced heavily by regulatory and reimbursement reforms.
- Price projections suggest a gradual decline in net prices, with steeper drops post-patent expiry.
- Strategic emphasis on innovation, formulary positioning, and value-based contracting is crucial to optimize profitability amid pricing pressures.
- Continuous monitoring of biosimilar approvals, patent statuses, and policy shifts is essential for informed decision-making.
FAQs
1. When will biosimilar competition likely impact the pricing of NDC 00527-1698?
The biosimilar market is anticipated to accelerate significantly post [patent expiry date, e.g., 2025], with notable biosimilar entries expected within 1–2 years thereafter.
2. How do reimbursement policies influence the net price of this drug?
Reimbursement mechanisms, especially value-based contracts and negotiated discounts, can substantially lower net prices, encouraging formulary adoption and influencing overall market price trends.
3. Are there recent regulatory approvals that could alter the market landscape?
Yes, pending or recent FDA approvals of biosimilars and new indications can shift market share and pricing strategies, necessitating ongoing regulatory monitoring.
4. What factors will sustain premium pricing for this product?
Exclusive patent rights, unique formulations, unmet clinical needs, and high brand loyalty sustain premium pricing levels until biosimilar competition becomes dominant.
5. How can stakeholders prepare for future price erosion?
Investing in differentiation through innovation, engaging in strategic negotiations with payers, and expanding indications can help preserve margins amid declining prices.
References
- [Industry Reports and Market Research Firms] (e.g., EvaluatePharma, IQVIA, GlobalData)[1].
- [Regulatory Agency Announcements] (FDA, EMA)[2].
- [Pricing & Reimbursement Data] (Medicaid, Medicare, private payers)[3].
- [Patent and Exclusivity Data] (Hatch-Waxman Database)[4].
- [Biosimilar Approvals and Market Entries] (BioPharmaceuticals Licensing Summit Reports)[5].
Note: Details specific to NDC: 00527-1698, including exact drug name, indications, and current market prices, should be verified through current pharmaceutical databases and regulatory filings for precise analysis.
More… ↓
